Drugs / VAC∆6 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05846243 | Oct → Dec 2021 | cowpox, monkeypox, smallpox, vaccinia | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAC∆6 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05846243 ↗ |
| Known as | OrthopoxVac | “Before applying for a state license to the Ministry of the Russian Federation on May 4, 2022, the VACΔ6 vaccine was renamed to OrthopoxVac.” NCT05846243 ↗ |
| Modality | Vaccine | “Live cell-based vaccine against smallpox and other orthopoxvirus infections” NCT05846243 ↗ |
| Route | Other | “single intradermal VAC∆6 dose” NCT05846243 ↗ |